Global Healthcare & Biotech — AI Drug Discovery GLP-1 Revolution
Healthcare is being revolutionised by AI-accelerated drug discovery, GLP-1 obesity drug demand (Novo Nordisk, Eli Lilly), and mRNA platform expansion. Biotech pipelines are accelerating. The sector combines defensive characteristics with explosive growth potential.
Stocks in this theme · Global healthcare & biotech
12 companies in this theme — showing top 12 by market cap.
| Symbol | Company | Price | Mkt Cap | Sector |
|---|---|---|---|---|
| LLY | Eli Lilly and | | Healthcare | | |
| JNJ | Johnson & Johnson |
Global Healthcare & Biotech Stocks 2025 — GLP-1 AI Drug DiscoveryThe GLP-1 revolution and AI drug discovery are reshaping global healthcare. Track Novo Nordisk, Eli Lilly, and biotech plays with SniperIQ. Page OverviewThis page is part of SniperIQ's market-intelligence library and is dedicated to Discover / Global Healthcare Biotech. It provides route-specific research context for search users before the full React application loads. Canonical URLhttps://sniperiq.ai/discover/global-healthcare-biotech SniperIQ Research Navigation
Theme Snapshot
Theme SummaryHealthcare is being revolutionised by AI-accelerated drug discovery, GLP-1 obesity drug demand (Novo Nordisk, Eli Lilly), and mRNA platform expansion. Biotech pipelines are accelerating. The sector combines defensive characteristics with explosive growth potential. Relevant Topics
Frequently Asked QuestionsWhat is GLP-1 and why does it matter for investors?GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) are blockbuster obesity and diabetes drugs. The market is projected to reach $150B+ by 2030 — a transformative pharmaceutical wave. How to invest in biotech from India?Via US-listed biotech ETFs (XBI, IBB), direct US stock purchases through HDFC Securities/Motilal International, or Indian pharma ADRs like Dr Reddy's and Sun Pharma. | $614B | Healthcare |
| ABBV | AbbVie |
Global Healthcare & Biotech Stocks 2025 — GLP-1 AI Drug DiscoveryThe GLP-1 revolution and AI drug discovery are reshaping global healthcare. Track Novo Nordisk, Eli Lilly, and biotech plays with SniperIQ. Page OverviewThis page is part of SniperIQ's market-intelligence library and is dedicated to Discover / Global Healthcare Biotech. It provides route-specific research context for search users before the full React application loads. Canonical URLhttps://sniperiq.ai/discover/global-healthcare-biotech SniperIQ Research Navigation
Theme Snapshot
Theme SummaryHealthcare is being revolutionised by AI-accelerated drug discovery, GLP-1 obesity drug demand (Novo Nordisk, Eli Lilly), and mRNA platform expansion. Biotech pipelines are accelerating. The sector combines defensive characteristics with explosive growth potential. Relevant Topics
Frequently Asked QuestionsWhat is GLP-1 and why does it matter for investors?GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) are blockbuster obesity and diabetes drugs. The market is projected to reach $150B+ by 2030 — a transformative pharmaceutical wave. How to invest in biotech from India?Via US-listed biotech ETFs (XBI, IBB), direct US stock purchases through HDFC Securities/Motilal International, or Indian pharma ADRs like Dr Reddy's and Sun Pharma. | $450B | Healthcare |
| UNH | UnitedHealth Group | $432.15 | 92B | Healthcare |
| MRK | Merck & | | 16B | Healthcare | |
| AMGN | Amgen | 67.25 | | Healthcare | |
| TMO | Thermo Fisher Scientific | $523.79 | | Healthcare | |
| ABT | Abbott Laboratories | | Healthcare | | |
| PFE | Pfizer |
Global Healthcare & Biotech Stocks 2025 — GLP-1 AI Drug DiscoveryThe GLP-1 revolution and AI drug discovery are reshaping global healthcare. Track Novo Nordisk, Eli Lilly, and biotech plays with SniperIQ. Page OverviewThis page is part of SniperIQ's market-intelligence library and is dedicated to Discover / Global Healthcare Biotech. It provides route-specific research context for search users before the full React application loads. Canonical URLhttps://sniperiq.ai/discover/global-healthcare-biotech SniperIQ Research Navigation
Theme Snapshot
Theme SummaryHealthcare is being revolutionised by AI-accelerated drug discovery, GLP-1 obesity drug demand (Novo Nordisk, Eli Lilly), and mRNA platform expansion. Biotech pipelines are accelerating. The sector combines defensive characteristics with explosive growth potential. Relevant Topics
Frequently Asked QuestionsWhat is GLP-1 and why does it matter for investors?GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) are blockbuster obesity and diabetes drugs. The market is projected to reach $150B+ by 2030 — a transformative pharmaceutical wave. How to invest in biotech from India?Via US-listed biotech ETFs (XBI, IBB), direct US stock purchases through HDFC Securities/Motilal International, or Indian pharma ADRs like Dr Reddy's and Sun Pharma. | | Healthcare | |
| ISRG | Intuitive Surgical | 41.95 | | Healthcare | |
| VRTX | Vertex Pharmaceuticals | $471.74 | | Healthcare | |
| REGN | Regeneron Pharmaceuticals | $650.82 | $67B | Healthcare |
Research Coverage
- Novo Nordisk vs Eli Lilly: GLP-1 pipeline and market share war
- AI drug discovery picks: Recursion, Insilico, Schrödinger
- India pharma ADR: Dr Reddy's, Sun Pharma, Cipla
- Global biotech ETF: XBI vs IBB comparison
Parent Discover Hub
Discover Structural Investment Themes keeps this page inside the main discover cluster with sibling theme and workflow links.
Frequently Asked Questions
What is GLP-1 and why does it matter for investors?
GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) are blockbuster obesity and diabetes drugs. The market is projected to reach
How to invest in biotech from India?
Via US-listed biotech ETFs (XBI, IBB), direct US stock purchases through HDFC Securities/Motilal International, or Indian pharma ADRs like Dr Reddy's and Sun Pharma.